Patent Blue V dye anaphylaxis: Experience of Australian and New Zealand surgeons

ANZ Journal of Surgery

Volumn 84, Issue 1-2, 2014, Pages 37-41

  Wong, April ^a,b   Spillane, Andrew ^a,b,c  

^a Mater Hospital   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Anaphylaxis; Breast cancer; Patent Blue V; Sentinel lymph node biopsy

Indexed keywords

COLORING AGENT; DIAGNOSTIC AGENT; DISULFINE BLUE; FUCHSINE;

ANAPHYLAXIS; ARTICLE; AUSTRALIA; BREAST CANCER; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL PRACTICE; FEMALE; HEALTH CARE SURVEY; HEALTH PERSONNEL ATTITUDE; HUMAN; METHODOLOGY; NEW ZEALAND; PATHOLOGY; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; STATISTICS;

ANAPHYLAXIS; BREAST CANCER; PATENT BLUE V; SENTINEL LYMPH NODE BIOPSY;

ANAPHYLAXIS; ATTITUDE OF HEALTH PERSONNEL; AUSTRALIA; BREAST NEOPLASMS; COLORING AGENTS; FEMALE; HEALTH CARE SURVEYS; HUMANS; NEW ZEALAND; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; ROSANILINE DYES; SENTINEL LYMPH NODE BIOPSY;

EID: 84892874933     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2012.06277.x     Document Type: Article

References (34)

1. National Breast and Ovarian Cancer Centre. Sentinel node biopsy for early breast cancer: a systematic review. 2007 [Updated 29 May 2009, cited 22 Mar 2012.] Available from URL: http://canceraustralia.nbocc.org.au/view-document-details/snbrw-sentinel-node-biopsy-for-early-breast-cancer-a-systematic-review
2. National Institute for Health and Clinical Excellence Guideline. Breast cancer (early & locally advanced): diagnosis and treatment. Feb 2009 [Updated 3 March 2009, Cited 22 Mar 2012.] Available from URL: http://www.nice.org.uk/CG80
3. Gill G, Gillett D, Molland G etal. Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann. Surg. Oncol. 2009; 16: 266-275.
4. Veronesi U, Paganelli G, Viale G etal. Sentinel-lymph node biopsy as a staging procedure in breast cancer: update of a randomized controlled study. Lancet Oncol. 2006; 7: 983-990.
5. Krag DN, Anderson SJ, Julian TB etal. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007; 8: 881-888.
6. Mansel RE, Fallowfield L, Kissin M etal. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J. Natl Cancer Inst. 2006; 98: 599-609.
7. Montgomery LL, Thorne AC, Van Zee KJ etal. Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. Anesth. Analg. 2002; 95: 385-388.
8. White V, Harvey JR, Griffith CD, Youssef M, Carr M. Sentinel lymph node biopsy in early breast cancer surgery-working with the risks of vital blue dye to reap the benefits. Review. Eur. J. Surg. Oncol. 2011; 37: 101-108.
9. Cady B. Consensus on sentinel node biopsy. Breast J. 2002; 8: 123-125.
10. Platt P, Roberts L. Anaphylaxis to patent blue dye-misadventure or misdemeanour? Anaesth. Intensive Care 2011; 39: 166-167.
11. Howard JD, Moo V, Sivalingam P. Anaphylaxis and other adverse reactions to blue dyes: a case series. Anaesth. Intensive Care 2011; 39: 287-292.
12. Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a meta-analysis. Cancer 2006; 106: 4-16.
13. Del Bianco P, Zavagno G, Burelli P etal. Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomized clinical trial. Eur. J. Surg. Oncol. 2008; 34: 508-513.
14. Scherer K, Bircher AJ, Figueiredo V. Blue dyes in medicine-a confusing terminology. Contact Dermatitis 2006; 54: 231-232.
15. Scherer K, Studer W, Figueiredo V, Bircher AJ. Anaphylaxis to isosulfan blue and cross-reactivity to patent blue V: case report and review of the nomenclature of vital blue dyes. Ann. Allergy Asthma Immunol. 2006; 96: 497-500. Review.
16. Thevarajah S, Huston TL, Simmons RM. A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in sentinel lymph node biopsy for breast cancer. Am. J. Surg. 2005; 189: 236-239. Review.
17. Hunting AS, Nopp A, Johansson SG, Andersen F, Wilhelmsen V, Guttormsen AB. Anaphylaxis to Patent Blue V. I. Clinical aspects. Allergy 2010; 65: 117-123.
18. Daley MD, Norman PH, Leak JA etal. Adverse events associated with the intraoperative injection of isosulfan blue. J. Clin. Anesth. 2004; 16: 332-341.
19. Albo D, Wayne JD, Hunt KK etal. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am. J. Surg. 2001; 182: 393-398.
20. Johansson SG, Nopp A, Oman H, Stahl-Skov P, Hunting AS, Guttormsen AB. Anaphylaxis to Patent Blue V. II. A unique IgE-mediated reaction. Allergy 2010; 65: 124-129.
21. Leong SP, Donegan E, Heffernon W, Dean S, Katz JA. Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma. Ann. Surg. Oncol. 2000; 7: 361-366.
22. King TA, Fey JV, Van Zee KJ etal. A prospective analysis of the effect of blue-dye volume on sentinel lymph node mapping success and incidence of allergic reaction in patients with breast cancer. Ann. Surg. Oncol. 2004; 11: 535-541.
23. Ingram D, Hewett L, Maddern P. Anaphylaxis to patent blue during sentinel lymph node biopsy. ANZ J. Surg. 2004; 74: 607-608.
24. Barthelmes L, Goyal A, Newcombe RG, McNeill F, Mansel RE; NEW START and ALMANAC Study Groups. Adverse reactions to patent blue V dye - the NEW START and ALMANAC experience. Eur. J. Surg. Oncol. 2010; 36: 399-403.
25. Mutual Benefit Marketing. MBM Food Additives Guide, 2001 [Updated January 2010, Cited 19 Feb 2012.] Available from URL: http://mbm.net.au/health/100-181.htm
26. Food Standards Australia New Zealand. Food Standards Information Service, Notification Circular 10-03, 10-05, 2003 [Updated 14 June 2012, cited 26 Apr 2012.] Available from URL: http://www.foodstandards.gov.au/search/?keywords=patent+blue+v
27. Kalimo K, Jansén CT, Kormano M. Sensitivity to Patent Blue dye during skin-prick testing and lymphography. A retrospective and prospective study. Radiology 1981; 141: 365-367.
28. World Allergy Organization. Allergy to Anesthetic Agents. 2007 [Updated 2 October 2007, cited 11 Mar 2012.] Available from URL: http://www.worldallergy.org/professional/allergic_diseases_center/anaesthetic_agents/
29. Wilke LG, McCall LM, Posther KE etal. Surgical complications associated with sentinel lymph node biopsy: results from a Prospective International Cooperative Group trial. Ann. Surg. Oncol. 2006; 13: 491-500.
30. Barbaud A, Gonçalo M, Bruynzeel D, Bircher A, European Society of Contact Dermatitis. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001; 45: 321-328.
31. Australasian society of clinical immunology and allergy. Skin pick testing for the diagnosis of allergic disease guideline, 2006 [Updated 7 March 2009, cited 27 Mar 2012.] Available from URL: http://www.allergy.org.au/health-professionals/papers/skin-prick-testing
32. Aberer W, Bircher A, Romano A etal. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. European Network for Drug Allergy (ENDA); EAACI interest group on drug hypersensitivity. Allergy 2003; 58: 854-863.
33. Crivellaro M, Senna G, Dama A, Bonadonna P, Passalacqua G. Anaphylaxis due to patent blue dye during lymphography, with negative skin prick test. J. Investig. Allergol. Clin. Immunol. 2003; 13: 71-72.
34. Bernstein DI, Wanner M, Borish L, Liss GM, Immunotherapy Committee, American Academy of Allergy, Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J. Allergy Clin. Immunol. 2004; 113: 1129-1136.